Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HABA LABORATORIESTSE:4925 55 Debt-to-EBITDA is 0.55 as of Mar. 2026, which is 54% below its 10-year median of 1.19. GuruFocus rates TSE:4925 with a GF Score™ of 55/100 and a GF Value™ of 円1,966.37 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 1,563 Consumer Packaged Goods companies, HABA LABORATORIES ranks better than 67.88% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for HABA LABORATORIES's Debt-to-EBITDA or its related term are showing as below:
TSE:4925'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.79 Med: 1.19 Max: 119.25
Current: 1.01
During the past 13 years, the highest Debt-to-EBITDA Ratio of HABA LABORATORIES was 119.25. The lowest was -1.79. And the median was 1.19.
TSE:4925's Debt-to-EBITDA is ranked better than 67.88% of 1563
companies
in the Consumer Packaged Goods industry
Industry Median: 2.09
vs TSE:4925: 1.01
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
HABA LABORATORIES Debt-to-EBITDA Related Terms
HABA LABORATORIES Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for HABA LABORATORIES's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4925 vs PG, CL, KVUE: Debt-to-EBITDA Comparison
For the Household & Personal Products subindustry, HABA LABORATORIES's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HABA LABORATORIES Debt-to-EBITDA vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, HABA LABORATORIES's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where HABA LABORATORIES's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
HABA LABORATORIES (TSE:4925) has a Debt-to-EBITDA of 0.55 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on HABA LABORATORIES. This is 54% below median its historical median of 1.19. According to the industry distribution chart, HABA LABORATORIES ranks #502 out of 1563 companies in the Consumer Packaged Goods industry, placing it in the top 32.1%.
Is HABA LABORATORIES's Debt-to-EBITDA too high?
HABA LABORATORIES's current Debt-to-EBITDA of 0.55 is 54% below median its 10-year median of 1.19. The Consumer Packaged Goods industry median Debt-to-EBITDA is 2.09. HABA LABORATORIES's value of 0.55 is 73.7% below this industry median. Based on the distribution chart, HABA LABORATORIES ranks #502 out of 1563 companies in the Consumer Packaged Goods industry, which is above the industry midpoint. Overall, HABA LABORATORIES has a GF Score™ of 55/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does HABA LABORATORIES's Debt-to-EBITDA compare to PG and CL?
According to the Consumer Packaged Goods industry distribution chart, HABA LABORATORIES ranks #502 out of 1563 companies for Debt-to-EBITDA. This puts HABA LABORATORIES in the upper half of its industry. The industry median Debt-to-EBITDA is 2.09. HABA LABORATORIES's value of 0.55 is 73.7% below this benchmark. While the company's 10-year median is 1.19 vs. the industry median of 2.09, HABA LABORATORIES has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Consumer Packaged Goods company?
The median Debt-to-EBITDA among Consumer Packaged Goods companies is 2.09, based on 1,563 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. HABA LABORATORIES's current Debt-to-EBITDA of 0.55 is 73.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on HABA LABORATORIES. For the Consumer Packaged Goods industry, the median Debt-to-EBITDA is 2.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HABA LABORATORIES's current Debt-to-EBITDA is 0.55, which is 54% below median its own 10-year median of 1.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HABA LABORATORIES stock overvalued right now?
Based on GuruFocus' analysis, HABA LABORATORIES (TSE:4925) is currently considered Modestly Undervalued. The stock's GF Value™ is 円1,966.37, compared to a current price of 円1,727.00 — trading 12.2% below its estimated fair value. The current Debt-to-EBITDA is 0.55, which is 54% below median its 10-year median of 1.19 and 73.7% below the Consumer Packaged Goods industry median of 2.09. HABA LABORATORIES's overall GF Score™ is 55/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For HABA LABORATORIES (TSE:4925), the current Debt-to-EBITDA is 0.55 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HABA LABORATORIES (TSE:4925) Overvalued in 2026?
Based on GuruFocus' analysis, HABA LABORATORIES stock appears to be undervalued.
The current stock price of 円1,727.00 is trading 12.2% below its estimated GF Value™ of 円1,966.37.
GuruFocus considers HABA LABORATORIES to be Modestly Undervalued.
Key valuation signals for TSE:4925:
Debt-to-EBITDA: 0.55 (54% below median its 10-year median of 1.19)
GF Value™: 円1,966.37 vs. price of 円1,727.00 (12.2% below fair value)
Industry Position: 73.7% below the Consumer Packaged Goods median (#502 of 1563)
No single metric tells the full story. See the TSE:4925 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HABA LABORATORIES Inc along with its subsidiaries develops, manufactures and distributes natural cosmetics, quasi-drugs and nutritional supplements. The company sells its products through shops, delivery centers, mail order, and the Internet.
55GF Score
Get the complete analysis for TSE:4925
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4925 has been successfully added to your 
